---
title: "Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical presentation - signs and symptoms"
description: "Formulary evidence on Envudeucitinib (ESK-001, FTP-637) in Moderate-to-severe plaque psoriasis: Clinical presentation - signs and symptoms. Topics: Skin lesions: well-demarcated plaques with silvery-white scale on extensor surfaces, trunk, and scalp; Skin symptoms: itching, redness, flaking, and scales in patient survey; Pruritus: lifetime and point prevalence; Most bothersome symptoms: itching, scales, and flaking; 5 further topics. 9 evidence topics quoted from 6 sources."
canonical: "https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description/clinical-presentation-signs-and-symptoms"
published: "2026-11-19T12:09:07-05:00"
modified: "2026-11-19T12:09:07-05:00"
---

# Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical presentation - signs and symptoms

<a id="heading-2.2.1.6"></a>

## 2.2.1.6 Clinical Presentation - Signs and Symptoms

<a id="topic-2.2.1.6-1"></a>

### Skin lesions: well-demarcated plaques with silvery-white scale on extensor surfaces, trunk, and scalp

> “The most common form is plaque psoriasis, which presents as well-demarcated salmon pink plaques with silvery-white scale, typically in a symmetrical distribution and affecting the extensor surfaces (especially elbows and knees), trunk and scalp (Fig 1). Bleeding points may be noted where scales have been removed (Auspitz sign).”
> “Koebner phenomenon describes the appearance of psoriasis at skin areas affected by trauma.”

Source: [Raharja et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8140694/)

<a id="topic-2.2.1.6-2"></a>

### Skin symptoms: itching, redness, flaking, and scales in patient survey

> “Patients commonly reported PsO involvement in special areas, and more than half of patients had scalp involvement (Table 2). Most patients reported PsO symptoms; itching, redness, flaking, and scales occurred in ~ 90% of patients or more (Table 2).”

Source: [Lebwohl et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8547901/)

<a id="topic-2.2.1.6-3"></a>

### Pruritus: lifetime and point prevalence

> “Pruritus ever in the course of psoriasis (the lifetime prevalence of pruritus) was experienced by the great majority (92.9%) of patients, while 81% reported the presence of this symptom within the 3 days preceding the examination (the point prevalence of pruritus).”

Source: [Jaworecka et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8304988/)

<a id="topic-2.2.1.6-4"></a>

### Most bothersome symptoms: itching, scales, and flaking

> “Psoriasis patients indicated that their most bothersome signs or symptoms were itching (43%), scales (23%), and flaking (20%).”

Source: [Lebwohl et al. (2014)](https://pubmed.ncbi.nlm.nih.gov/24576585/)

<a id="topic-2.2.1.6-5"></a>

### Nail involvement: pitting, onycholysis, and dystrophy

> “Nails may be affected in up to 50% of patients and may manifest as nail pitting (indentation in the nails), onycholysis (separation of nail plate from nail bed), oil spots (discoloration of the nailbed), dystrophy and subungual hyperkeratosis.”

Source: [Raharja et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8140694/)

<a id="topic-2.2.1.6-6"></a>

### Nail involvement: prevalence and associated severity in 3,531 patients

> “Nail psoriasis was diagnosed in 40·9% of the patients; prevalence was 11·2 percentage points higher in men than in women.”
> “Patients with nail involvement had a longer disease duration (21·9 vs. 18·1 years), higher disease severity (mean Psoriasis Area and Severity Index 12·7 vs. 9·3), higher frequency of PsA (26·0% vs. 12·7%), stronger impairment of HRQoL (mean Dermatology Life Quality Index 8·9 vs. 7·3), and a 2·5-fold higher rate of inpatient treatments.”

Source: [Augustin et al. (2010)](https://pubmed.ncbi.nlm.nih.gov/20456340/)

<a id="topic-2.2.1.6-7"></a>

### Genital involvement: prevalence, itch, pain, and dyspareunia

> “One hundred thirty-four patients (38%) had current genital involvement while 224 (63%) had a current and/or previous history of genital involvement. Eighty-seven percent reported itch, 39% pain, 42% dyspareunia, 32% a worsening of their genital psoriasis after intercourse, and 43% a decreased frequency of intercourse.”

Source: [Ryan et al. (2015)](https://pubmed.ncbi.nlm.nih.gov/25824273/)

<a id="topic-2.2.1.6-8"></a>

### High-impact sites: scalp, face, nails, genitalia, palms, and soles

> “High-impact and difficult-to-treat psoriasis sites include scalp, face, nails, genitalia, palms and soles.”

Source: [Raharja et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8140694/)

<a id="topic-2.2.1.6-9"></a>

### Musculoskeletal symptoms: joint discomfort in patients with psoriasis alone

> “Among patients with PsO alone (n = 2550), 58% reported experiencing joint discomfort; of these (n = 1485), 63% had ≤ 4 involved joints (consistent with oligoarthritis). When asked if they have experienced PsA symptoms, many patients with PsO alone reported morning stiffness of the joints (44%), nail involvement (32%), pain and/or swelling of the feet (24%), or”

Source: [Lebwohl et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8547901/)

## Related pages
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Terms and abbreviations](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/terms-and-abbreviations.md)
- [Envudeucitinib (ESK-001): Moderate-to-severe plaque psoriasis](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/executive-summary.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Product information and disease description](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/product-information-and-disease-description.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Clinical evidence](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/clinical-evidence.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: Economic information and modeling report](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/economics.md)
- [Envudeucitinib (ESK-001) in Moderate-to-severe plaque psoriasis: References](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references) · [Markdown](https://www.evicenter.com/drugs/envudeucitinib--moderate-to-severe-plaque-psoriasis/references.md)
